We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » FDA Offers Advice on Standardizing Real-World Data for IND Submissions
FDA Offers Advice on Standardizing Real-World Data for IND Submissions
The FDA has acknowledged the challenges sponsors face in standardizing study data taken from real-world data (RWD) sources and issued draft guidance for sponsors including RWD as study data in their requests for clinical trial authorization.